PLPer LjungmanMD, PhDSlideset26th International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2025Current and Future Treatments in Cytomegalovirus: Maribavir, Letermovir, Vaccines, mABs - Per LjungmanView Slideset
DLTDavid L. ThomasMDSlidesetViral Hepatitis and Liver Disease26th International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2025What Is Next for HCV? - David L. ThomasView Slideset
ATAlfredo TagarroPhD, MDSlideset26th International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2025The Role of MoAbs: Challenges in Prevention and Treatment of Infectious Diseases in Children - Alfredo TagarroView Slideset
LRCLauren R. CirrincionePharmD, MPHSlideset26th International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2025Hormonal Effects on Drug Metabolism and Transporters - Lauren R. CirrincioneView Slideset
SSSoumitra SamantaMSc, MTech, PhDSlideset26th International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2025Integration of Machine Learning for Predictive Pharmacometric Assessments - Soumitra SamantaView Slideset
ERElias RosenPhDSlidesetHIV26th International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2025Abstract #21 Longitudinal Monitoring of Cabotegravir and Rilpivirine Exposure from Hair Strand Concentrations - Elias RosenView Slideset
SlidesetHIV26th International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2025Abstract #20 An Enzymatic Assay with Lateral Flow Readout for Measurement of Tenofovir Diphosphate and Long-Term HIV Medication Adherence - Carrie LinView Slideset
SlidesetHIVViral Hepatitis and Liver Disease26th International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2025Abstract #19 Assessing ChatGPT’s Capability in Understanding and Reporting Antiretroviral Therapy Drug-Drug Interaction Effects: Quantitative and Qualitative Results from the ACCURATE-DDI Study - Erin ReadyView Slideset
JCJon CollinsPharmDSlidesetHIV26th International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2025Abstract #17 Lack of Clinically Significant Drug–Drug Interactions Between the Third-Generation Integrase Strand Transfer Inhibitor VH4524184 (VH-184) and Combined Oral Contraceptives - Jon CollinsView Slideset
AOAndrew OwenBSS, MSC, PhD, FSBSlidesetHIV26th International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2025Abstract #35 Can Low-Cost Oral Alternatives Be Used in Place of Oral Lenacapavir When Initiating Long-Acting Lenacapavir PrEP in Low- and Middle-Income Countries? - Andrew OwenView Slideset
SlidesetHIV26th International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2025Abstract #16 Inter- and Intraindividual Variability of Long-Acting Cabotegravir/Rilpivirine Pharmacokinetics after 1 Year of Continuous Use - Shawnalyn SunagawaView Slideset
SlidesetHIV26th International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2025Abstract #15 Pharmacokinetics of Long-Acting Cabotegravir and Rilpivirine in Virologically Suppressed Adolescents Living with HIV-1 in Sub-Saharan Africa: Data from the LATA Trial - Lisanne BeversView Slideset
